Coloured Lilliputian Hallucinations with Amantadine

R. Harper,BARBARA U. C. Knothe
DOI: https://doi.org/10.5694/j.1326-5377.1973.tb110479.x
1973-03-01
Abstract:SCHWAD et alii (1969) described the remission of Parkinsonian symptoms in a 58-year-old woman while she was receiving amantadine hydrochloride as a prophylactic antiviral agent. This chance observation led them to conduct a trial of amantadine hydrochloride in patients with Parkinson's disease. They found that 66% of patients showed subjective or objective improvement. This finding has been confirmed in several other trials (e.g., Parkes et alii, 1970; Gilligan et alii, 1970; Schwieger and Jenkins, 1970). Schwab et alii (1969) suggested that the eft'ective therapeutic dose is 200 mg daily, and that doses higher than this have no increased beneficial eft'ect and may increase side eft'ects. This mode of treatment is now used either separately or with t-dopa, We report three patients whose presenting symptoms of Lilliputian hallucinations seemed to be especially related to amantadine therapy.
What problem does this paper attempt to address?